- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03328663
Psychological Intervention for Caregivers of Patients Undergoing Stem Cell Transplant
Randomized Trial of a Psychological Intervention to Promote Coping for Caregivers of Patients Undergoing Hematopoietic Stem Cell Transplantation (HCT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to find out whether a psychological intervention can make the experience of being a caregiver more manageable by improving the participant's quality of life, mood, and caregiving burden during the participant's loved one's transplant process.
The psychological intervention will entail six visits with a trained clinician and will take place during the first three months of the participant's loved ones' transplant process. A trained behavioral psychologist or social worker will meet with the participant or talk with the participant over the telephone or video conference for 45 minutes at a time to discuss the participant's caregiver experience and to help the participant develop effective skills to support the participant's loved one as well as participant over the course of the transplant.
The study will use a series of questionnaires to measure the participant's quality of life, mood, and overall caregiving burden. Study questionnaires will be completed in the hospital or clinic. The participant will also have the option of completing these questionnaires remotely through a secure web link, over the telephone, or in a mailed paper copy.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult caregivers (≥18 years) of patients undergoing autologous or allogeneic HCT at MGH, and they must attend the HCT consent visit with the patient.
- A relative or a friend who either lives with the patient or has in-person contact with him or her at least twice per week and is identified as the primary caregiver for transplant.
- Ability to speak English or able to complete questionnaires with minimum assistance of an interpreter.
Exclusion Criteria:
• Significant uncontrolled psychiatric or other co-morbid disease, which the primary oncologist believes prohibits the ability to participate in study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CARE intervention
|
Promote effective coping and reduce caregiving burden.
|
Active Comparator: Standard transplant care
|
Promote effective coping and reduce caregiving burden.
Standard cared administered by the hospital.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of the intervention (feasibility description below)
Time Frame: 2 years
|
Feasibility defined if at least 60% of eligible caregivers are enrolled in the study and attend at least 50% of the intervention visits
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare Caregiver QOL (CarGOQOL) between the study arms
Time Frame: up to day +90
|
we will compare caregiver QOL as measured by CarGOQOL at day +30 and day +90 after the intervention (adjusting for baseline values)
|
up to day +90
|
Compare caregiving burden (CRA) between the study arms
Time Frame: up to day +90
|
we will compare caregiver caregiving burden as measured by Caregiver Reaction Assessment (CRA) at day +30 and day +90 after the intervention (adjusting for baseline values)
|
up to day +90
|
Compare caregiver mood (HADS) between the study arms
Time Frame: up to day +90
|
We will compare caregiver mood use the Hospital Anxiety and Depression Scale (HADS) at day +30 and day +90 (controlling for baseline values).
The HADS includes two subscales: depression (range 0 (no distress) to 21 (maximum distress) and anxiety (range 0 (no distress) and 21 (maximum distress))
|
up to day +90
|
Compare caregiver self-efficacy (CASE-t) between the study arms
Time Frame: up to day +90
|
We will compare caregiver self-efficacy using the Cancer Self-Efficacy Scale-transplant (CASE-t) at day +30 and day +90 (controlling for baseline values).
The scale ranges from 0 to 170 with higher scores indicate higher self efficacy
|
up to day +90
|
Compare perceived coping skills (MOCS) between the study arms
Time Frame: up to day +90
|
Compare caregiver coping skills using the Measure of Current Status (MOCS) between the study arms.
Score ranges from 0-52, with higher scores indicating higher coping skills
|
up to day +90
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Areej El-Jawahri, MD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 17-476
- CA087723 (Other Grant/Funding Number: NCI)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on CARE
-
Kaiser PermanenteNot yet recruitingAttention-deficit HyperactivityUnited States
-
Maastricht University Medical CenterMaastricht UniversityCompleted
-
Evandro Chagas Institute of Clinical ResearchAlejandro Marcel Hasslocher Moreno, MD MSc PhD student; Andrea Costa, MD PhD; Andrea Silvestre de Sousa, MD PhD and other collaboratorsUnknownChagas Heart DiseaseBrazil
-
KU LeuvenUniversitaire Ziekenhuizen KU LeuvenCompletedStroke | Frailty | Hip FracturesBelgium
-
Carlos III Health InstituteHealth Department of the Basque GovernmentCompleted
-
Johns Hopkins Bloomberg School of Public HealthRecruitingBreast CancerUnited States
-
University Hospital, BordeauxCompletedChronic Kidney DiseaseFrance
-
Kronikerenheden NordjyllandCompletedChronic Obstructive Pulmonary Disease (COPD)Denmark
-
University of Lausanne HospitalsNational Heart, Lung, and Blood Institute (NHLBI); Swiss National Science FoundationCompletedPulmonary EmbolismSwitzerland, France, United States, Belgium
-
Vanderbilt UniversityCompletedMidwifery | Prenatal Care | Maternal Health Services | Perinatal Care | Maternal-child Health ServicesUnited States